OraSure Reports 29% Revenue Drop in Q4 2025, Eyes Regulatory Clearances for Growth
Event summary
- Q4 2025 revenue dropped 29% YoY to $26.8M, with core business revenue down 22% YoY.
- GAAP operating loss widened to $20.1M from $12.4M YoY, while non-GAAP operating loss reached $15.2M.
- Submitted FDA applications for rapid molecular self-test for Chlamydia/Gonorrhoeae and Colli-Pee™ urine collection device.
- Received Health Canada license for OraQuick™ HIV Self-Test, distributed by St. Michael’s Hospital.
- Guided Q1 2026 revenue to $26M–$29M, with negligible COVID-19 testing revenues.
The big picture
OraSure’s Q4 2025 results reflect the broader decline in COVID-19-related revenues and funding constraints in the diagnostics sector. The company is betting on regulatory clearances for new products to drive growth, positioning itself in the decentralized diagnostics market. Success hinges on navigating regulatory hurdles and executing cost discipline amid a competitive landscape.
What we're watching
- Regulatory Approvals
- The pace at which FDA clearance is secured for the rapid molecular self-test and Colli-Pee™ device will determine OraSure’s growth trajectory in 2026.
- Core Business Recovery
- Whether OraSure can stabilize and grow its core diagnostics and sample management solutions revenues amid a challenging funding environment.
- Cost Management
- How effectively OraSure can control operating expenses to improve profitability, given the widening GAAP and non-GAAP operating losses.
Related topics